vs
博士伦（BLCO）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
罗布乐思的季度营收约是博士伦的1.0倍（$1.4B vs $1.4B），博士伦净利率更高（-4.1% vs -22.3%，领先18.2%），罗布乐思同比增速更快（43.2% vs 9.8%），罗布乐思自由现金流更多（$308.6M vs $60.0M），过去两年罗布乐思的营收复合增速更高（32.9% vs 13.1%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
BLCO vs RBLX — 直观对比
营收规模更大
RBLX
是对方的1.0倍
$1.4B
营收增速更快
RBLX
高出33.4%
9.8%
净利率更高
BLCO
高出18.2%
-22.3%
自由现金流更多
RBLX
多$248.6M
$60.0M
两年增速更快
RBLX
近两年复合增速
13.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $1.4B |
| 净利润 | $-58.0M | $-316.0M |
| 毛利率 | — | 77.7% |
| 营业利润率 | 8.0% | -25.3% |
| 净利率 | -4.1% | -22.3% |
| 营收同比 | 9.8% | 43.2% |
| 净利润同比 | -1833.3% | -43.9% |
| 每股收益（稀释后） | $-0.16 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCORBLX
| Q4 25 | $1.4B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $1.1B | $1.0B | ||
| Q4 24 | $1.3B | $988.2M | ||
| Q3 24 | $1.2B | $919.0M | ||
| Q2 24 | $1.2B | $893.5M | ||
| Q1 24 | $1.1B | $801.3M |
净利润BLCORBLX
| Q4 25 | $-58.0M | $-316.0M | ||
| Q3 25 | $-28.0M | $-255.6M | ||
| Q2 25 | $-62.0M | $-278.4M | ||
| Q1 25 | $-212.0M | $-215.1M | ||
| Q4 24 | $-3.0M | $-219.6M | ||
| Q3 24 | $4.0M | $-239.3M | ||
| Q2 24 | $-151.0M | $-205.9M | ||
| Q1 24 | $-167.0M | $-270.6M |
毛利率BLCORBLX
| Q4 25 | — | 77.7% | ||
| Q3 25 | — | 78.2% | ||
| Q2 25 | — | 78.2% | ||
| Q1 25 | — | 78.3% | ||
| Q4 24 | — | 77.9% | ||
| Q3 24 | — | 77.7% | ||
| Q2 24 | — | 77.8% | ||
| Q1 24 | — | 77.7% |
营业利润率BLCORBLX
| Q4 25 | 8.0% | -25.3% | ||
| Q3 25 | 7.4% | -21.8% | ||
| Q2 25 | -0.9% | -29.8% | ||
| Q1 25 | -7.3% | -24.6% | ||
| Q4 24 | 6.8% | -24.7% | ||
| Q3 24 | 3.6% | -30.4% | ||
| Q2 24 | 2.1% | -26.6% | ||
| Q1 24 | 0.5% | -37.7% |
净利率BLCORBLX
| Q4 25 | -4.1% | -22.3% | ||
| Q3 25 | -2.2% | -18.8% | ||
| Q2 25 | -4.9% | -25.8% | ||
| Q1 25 | -18.6% | -20.8% | ||
| Q4 24 | -0.2% | -22.2% | ||
| Q3 24 | 0.3% | -26.0% | ||
| Q2 24 | -12.4% | -23.0% | ||
| Q1 24 | -15.2% | -33.8% |
每股收益（稀释后）BLCORBLX
| Q4 25 | $-0.16 | $-0.44 | ||
| Q3 25 | $-0.08 | $-0.37 | ||
| Q2 25 | $-0.18 | $-0.41 | ||
| Q1 25 | $-0.60 | $-0.32 | ||
| Q4 24 | $-0.00 | $-0.32 | ||
| Q3 24 | $0.01 | $-0.37 | ||
| Q2 24 | $-0.43 | $-0.32 | ||
| Q1 24 | $-0.48 | $-0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $3.1B |
| 总债务越低越好 | $5.0B | $1.2B |
| 股东权益账面价值 | $6.4B | $394.5M |
| 总资产 | $14.0B | $9.6B |
| 负债/权益比越低杠杆越低 | 0.78× | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资BLCORBLX
| Q4 25 | $383.0M | $3.1B | ||
| Q3 25 | $310.0M | $2.9B | ||
| Q2 25 | $266.0M | $2.6B | ||
| Q1 25 | $202.0M | $2.7B | ||
| Q4 24 | $305.0M | $2.4B | ||
| Q3 24 | $329.0M | $2.3B | ||
| Q2 24 | $285.0M | $2.4B | ||
| Q1 24 | $315.0M | $2.4B |
总债务BLCORBLX
| Q4 25 | $5.0B | $1.2B | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $4.8B | $1.2B | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — | ||
| Q1 24 | $4.6B | — |
股东权益BLCORBLX
| Q4 25 | $6.4B | $394.5M | ||
| Q3 25 | $6.4B | $407.6M | ||
| Q2 25 | $6.4B | $353.2M | ||
| Q1 25 | $6.4B | $310.7M | ||
| Q4 24 | $6.5B | $221.4M | ||
| Q3 24 | $6.6B | $189.9M | ||
| Q2 24 | $6.5B | $121.5M | ||
| Q1 24 | $6.7B | $71.6M |
总资产BLCORBLX
| Q4 25 | $14.0B | $9.6B | ||
| Q3 25 | $13.8B | $8.6B | ||
| Q2 25 | $13.8B | $7.8B | ||
| Q1 25 | $13.4B | $7.5B | ||
| Q4 24 | $13.5B | $7.2B | ||
| Q3 24 | $13.5B | $6.7B | ||
| Q2 24 | $13.3B | $6.5B | ||
| Q1 24 | $13.3B | $6.3B |
负债/权益比BLCORBLX
| Q4 25 | 0.78× | 2.98× | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.76× | — | ||
| Q4 24 | 0.74× | 5.48× | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.71× | — | ||
| Q1 24 | 0.69× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | $607.0M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $308.6M |
| 自由现金流率自由现金流/营收 | 4.3% | 21.8% |
| 资本支出强度资本支出/营收 | 5.4% | 21.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-66.0M | $1.4B |
8季度趋势，按日历期对齐
经营现金流BLCORBLX
| Q4 25 | $136.0M | $607.0M | ||
| Q3 25 | $137.0M | $546.2M | ||
| Q2 25 | $35.0M | $199.3M | ||
| Q1 25 | $-25.0M | $443.9M | ||
| Q4 24 | $22.0M | $184.5M | ||
| Q3 24 | $154.0M | $247.4M | ||
| Q2 24 | $15.0M | $151.4M | ||
| Q1 24 | $41.0M | $238.9M |
自由现金流BLCORBLX
| Q4 25 | $60.0M | $308.6M | ||
| Q3 25 | $63.0M | $443.6M | ||
| Q2 25 | $-54.0M | $176.7M | ||
| Q1 25 | $-135.0M | $426.5M | ||
| Q4 24 | $-70.0M | $120.6M | ||
| Q3 24 | $94.0M | $218.0M | ||
| Q2 24 | $-57.0M | $111.7M | ||
| Q1 24 | $-26.0M | $192.3M |
自由现金流率BLCORBLX
| Q4 25 | 4.3% | 21.8% | ||
| Q3 25 | 4.9% | 32.6% | ||
| Q2 25 | -4.2% | 16.3% | ||
| Q1 25 | -11.9% | 41.2% | ||
| Q4 24 | -5.5% | 12.2% | ||
| Q3 24 | 7.9% | 23.7% | ||
| Q2 24 | -4.7% | 12.5% | ||
| Q1 24 | -2.4% | 24.0% |
资本支出强度BLCORBLX
| Q4 25 | 5.4% | 21.1% | ||
| Q3 25 | 5.8% | 7.5% | ||
| Q2 25 | 7.0% | 2.1% | ||
| Q1 25 | 9.7% | 1.7% | ||
| Q4 24 | 7.2% | 6.5% | ||
| Q3 24 | 5.0% | 3.2% | ||
| Q2 24 | 5.9% | 4.4% | ||
| Q1 24 | 6.1% | 5.8% |
现金转化率BLCORBLX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 38.50× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
RBLX
暂无分部数据
